Jun 2026 (Q2 FY26) — Jul 31, 2026
AptarGroup Q2 FY26 — Adjusted EPS above guidance, strong Pharma performance
Read the full callAptarGroup (ATR) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
AptarGroup earnings: last reported Fri, 31 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1,027 | +6.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 12.3 | −2.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 87.6 | −21.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
27 of 28 judged targets kept · 24 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Adjusted EPS | $1.32 to $1.40 per share | Mar 2026 | Adjusted earnings per share were $1.42 compared to the prior year's adjusted earnings per share of $1.68 at comparable exchange rates. | Achieved |
| Adjusted EPS | $1.45 to $1.53 | Jun 2026 | We -- we anticipate third quarter adjusted earnings per share to be in the range of $1.45 to $1.53. | New |
| Effective Tax Rate | 21% to 23% | Dec 2025 | Our adjusted effective tax rate for the quarter was 22.6% compared to the prior year's 25.8% due to a more favorable mix of earnings and greater excess tax benefits from share-based compensation. | Diluted |
1 of APTARGROUP, INC.'s 52 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 49 more targets are in the full ledger.
Claimed
- All three segments delivered positive sales growth in Q2 FY26.
- Adjusted EPS of $1.42 was above the guidance range, driven by better-than-expected Pharma performance.
- Pharma segment core sales, excluding emergency medicine, grew by 8% in Q2 FY26.
- Beauty segment benefited from double-digit core sales growth in prestige fragrance.
- Closures segment saw strong beverage demand, particularly in bottled water, leading to 14% core sales growth in beverages.
Qualified
- Adjusted EBITDA decreased 3% to $213 million, with adjusted EBITDA margin declining to 20.7% from 22.6% YoY, primarily due to less favorable product mix and operational challenges in Beauty and Closures.
- Adjusted EPS of $1.42 was down 15% year-over-year at comparable exchange rates, impacted by lower emergency medicine sales, operational issues, and higher depreciation/amortization and interest expense.
- Pharma core sales were impacted by an anticipated $65 million decrease in emergency medicine sales for FY26, with approximately two-thirds incurred in H1 FY26.
- Beauty's adjusted EBITDA margin declined 190 basis points year-over-year to 12.2%, attributed to lower product volumes, unfavorable mix, and timing of resin pass-throughs.
- Closures' adjusted EBITDA margin declined 200 basis points year-over-year to 14.9%, temporarily impacted by new production line ramp-up and maintenance initiatives.
Price
$124.51 +0.20% · +$0.25
Performance −2.8% 1Y
1Y: $128.1 on 15 Oct 2025 → $124.51. High $145.72 (23 Feb 2026), low $111.94 (8 Jun 2026).
- Previous close
- $124.26
- 52-week range
- $111.94 – $145.72
- One year
- −3.60%
Overview
- Symbol
- ATR
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
27 of 28 judged targets kept · 24 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Adjusted EPS | $1.32 to $1.40 per share | Mar 2026 | Adjusted earnings per share were $1.42 compared to the prior year's adjusted earnings per share of $1.68 at comparable exchange rates. | Achieved |
| Adjusted EPS | $1.45 to $1.53 | Jun 2026 | We -- we anticipate third quarter adjusted earnings per share to be in the range of $1.45 to $1.53. | New |
| Effective Tax Rate | 21% to 23% | Dec 2025 | Our adjusted effective tax rate for the quarter was 22.6% compared to the prior year's 25.8% due to a more favorable mix of earnings and greater excess tax benefits from share-based compensation. | Diluted |
Claimed
- All three segments delivered positive sales growth in Q2 FY26.
- Adjusted EPS of $1.42 was above the guidance range, driven by better-than-expected Pharma performance.
- Pharma segment core sales, excluding emergency medicine, grew by 8% in Q2 FY26.
- Beauty segment benefited from double-digit core sales growth in prestige fragrance.
- Closures segment saw strong beverage demand, particularly in bottled water, leading to 14% core sales growth in beverages.
Qualified
- Adjusted EBITDA decreased 3% to $213 million, with adjusted EBITDA margin declining to 20.7% from 22.6% YoY, primarily due to less favorable product mix and operational challenges in Beauty and Closures.
- Adjusted EPS of $1.42 was down 15% year-over-year at comparable exchange rates, impacted by lower emergency medicine sales, operational issues, and higher depreciation/amortization and interest expense.
- Pharma core sales were impacted by an anticipated $65 million decrease in emergency medicine sales for FY26, with approximately two-thirds incurred in H1 FY26.
- Beauty's adjusted EBITDA margin declined 190 basis points year-over-year to 12.2%, attributed to lower product volumes, unfavorable mix, and timing of resin pass-throughs.
- Closures' adjusted EBITDA margin declined 200 basis points year-over-year to 14.9%, temporarily impacted by new production line ramp-up and maintenance initiatives.
The full ledger
Open APTARGROUP, INC.’s full ledger
A free account opens 5 company ledgers a month. All 52 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 1, 2026
AptarGroup Q1 FY26 — Mixed Performance with Pharma Destocking and Operational Challenges
Read the full callEvery analysed call
AptarGroup earnings calls (ATR)
Financials
What the filings say
Net profit, year on year: −22% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 909 | 848 | 887 | 966 | 961 | 963 | 983 | 1,027 |
| Expenses | 771 | 728 | 774 | 822 | 824 | 856 | 875 | 900 |
| Operating profit | 138 | 120 | 113 | 144 | 137 | 106 | 107 | 127 |
| Operating margin | 15.2% | 14.2% | 12.8% | 14.9% | 14.3% | 11.0% | 10.9% | 12.3% |
| Interest | 12 | 11 | 11 | 11 | 14 | 17 | 17 | 16 |
| Profit before tax | 131 | 116 | 106 | 140 | 154 | 92 | 94 | 115 |
| Tax rate | 23.8% | 13.1% | 25.8% | 20.0% | 17.1% | 18.9% | 22.4% | 23.5% |
| Net profit | 100 | 101 | 79 | 112 | 128 | 74 | 73 | 88 |
| EPS ($ per share) | 1.51 | — | 1.19 | 1.69 | 1.95 | — | 1.13 | 1.38 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reserves | 1,372 | 1,524 | 1,644 | 1,789 | 1,929 | 2,110 | 2,371 | 2,643 |
| Total liabilities | 1,955 | 1,990 | 2,139 | 2,157 | 2,135 | 2,131 | 1,946 | 2,567 |
| Fixed assets | 992 | 1,088 | 1,199 | 1,276 | 1,344 | 1,478 | 1,447 | 1,676 |
| Investments | — | 0 | 0 | 1 | 0 | 0 | 2 | 7 |
| Total assets | 3,378 | 3,562 | 3,990 | 4,141 | 4,203 | 4,452 | 4,432 | 5,253 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 314 | 514 | 570 | 363 | 479 | 575 | 643 | 570 |
| Cash from investing | -735 | -336 | -452 | -457 | -296 | -324 | -397 | -331 |
| Cash from financing | -15 | -197 | -74 | -82 | -162 | -172 | -225 | -77 |
| Net cash flow | -446 | -20 | 58 | -182 | 20 | 81 | 0 | 181 |
| Capital expenditure | -211 | -242 | -246 | -308 | -310 | -312 | -276 | -270 |
| Free cash flow | 102 | 272 | 324 | 56 | 168 | 263 | 367 | 300 |
ATR revenue by segment
| Segment | Q2 FY2024 | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Pharma | — | — | — | — | — | — | 45% | 45% | — |
| Beauty | — | — | — | — | — | — | 37% | 36% | — |
| Closures | — | — | — | — | — | — | 18% | 20% | — |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q2 FY2026 · share of revenue
- Europe 51% ↑ 2 pt
- North America 28% ↓ 4 pt
- Asia 13% ↑ 1 pt
- Latin America 8% ↑ 1 pt
As ATR cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
95 filings between Dec 12, 2025 and Sep 2, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$7.82M
18 sales by 8 insiders
Compensation
not trading decisions- 43
- Award — granted as compensation
- 3
- Option exercise — converted options into shares
- 31
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Ackerman Daniel | — | $1.82M | Dec 12, 2025 |
| Tanda Stephan B. | — | $1.34M | Aug 3, 2026 |
| Prieur Marc | — | $1.33M | Aug 4, 2026 |
| Tlili Hedi | — | $1.20M | Aug 3, 2026 |
| Touya Gael | — | $995.0K | Aug 27, 2026 |
| Vinczeller Shiela | — | $500.1K | Sep 2, 2026 |
| Gong Xiangwei | — | $487.8K | May 26, 2026 |
| Hudson Irene Elizabeth | — | $156.0K | May 7, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 2, 2026 | Vinczeller Shiela Chief Human Resources Officer | Sale | 765 | $99.7K |
| Sep 1, 2026 | Touya Gael President and CEO | Award | 2,637 | $0 |
| Aug 27, 2026 | Touya Gael Segment Pres., CEO Designate | Sale | 325 | $43.7K |
| Aug 27, 2026 | Touya Gael Segment Pres., CEO Designate | Sale | 3,415 | $456.5K |
| Aug 4, 2026 | Prieur Marc Segment President | Sale | 3,376 | $459.9K |
| Aug 4, 2026 | Prieur Marc Segment President | Sale | 124 | $17.0K |
| Aug 3, 2026 | Tanda Stephan B. President and CEO | Sale | 9,838 | $1.34M |
| Aug 3, 2026 | Tanda Stephan B. President and CEO | Option exercise | 9,838 | $735.8K |
| Aug 3, 2026 | Tlili Hedi Segment President | Sale | 8,854 | $1.20M |
| Jul 16, 2026 | Xing Julie Director | Award | 151 | $0 |
| Jul 16, 2026 | Owens B Craig Director | Award | 151 | $0 |
| Jul 16, 2026 | Kampouri Monnas Giovanna Director | Award | 151 | $0 |
| Jul 16, 2026 | Marey-Semper Isabel Director | Award | 151 | $0 |
| Jul 16, 2026 | FOTIADES GEORGE L Director | Award | 151 | $0 |
| Jul 16, 2026 | Matthews Candace S. Director | Award | 226 | $0 |
| Jul 16, 2026 | Trerotola Matthew L. Director | Award | 151 | $0 |
| Jul 16, 2026 | Wunderlich Ralf K. Director | Award | 151 | $0 |
| Jul 16, 2026 | Glickman Sarah JS Director | Award | 151 | $0 |
| Jun 15, 2026 | Gandhi Aditya CAO | Award | 2,664 | $0 |
| Jun 9, 2026 | Prieur Marc Segment President | Sale | 447 | $51.9K |
| Jun 9, 2026 | Prieur Marc Segment President | Sale | 4,553 | $526.0K |
| Jun 4, 2026 | Vinczeller Shiela Chief Human Resources Officer | Sale | 2,957 | $332.2K |
| Jun 4, 2026 | Vinczeller Shiela Chief Human Resources Officer | Sale | 385 | $43.7K |
| Jun 4, 2026 | Vinczeller Shiela Chief Human Resources Officer | Sale | 213 | $24.4K |
| May 26, 2026 | Gong Xiangwei President, Asia | Sale | 4,200 | $487.8K |
| May 21, 2026 | Tlili Hedi Segment President | Tax withheld | 688 | $80.2K |
| May 7, 2026 | Hudson Irene Elizabeth EVP and Chief Legal Officer | Sale | 842 | $103.9K |
| May 7, 2026 | Hudson Irene Elizabeth EVP and Chief Legal Officer | Option exercise | 842 | $93.8K |
| May 7, 2026 | Hudson Irene Elizabeth EVP and Chief Legal Officer | Sale | 422 | $52.1K |
| May 6, 2026 | Glickman Sarah JS Director | Award | 1,326 | $0 |
| May 6, 2026 | FOTIADES GEORGE L Director | Award | 1,326 | $0 |
| May 6, 2026 | Trerotola Matthew L. Director | Award | 1,326 | $0 |
| May 6, 2026 | Wunderlich Ralf K. Director | Award | 1,326 | $0 |
| May 6, 2026 | Xing Julie Director | Award | 1,326 | $0 |
| May 6, 2026 | Matthews Candace S. Director | Award | 1,552 | $0 |
| May 6, 2026 | Owens B Craig Director | Award | 1,326 | $0 |
| May 6, 2026 | Marey-Semper Isabel Director | Award | 1,326 | $0 |
| May 6, 2026 | Kampouri Monnas Giovanna Director | Award | 1,326 | $0 |
| May 1, 2026 | Tlili Hedi Segment President | Award | 7,196 | $0 |
| May 1, 2026 | Tlili Hedi Segment President | Tax withheld | 3,598 | $457.7K |
| May 1, 2026 | Touya Gael Segment Pres., CEO Designate | Tax withheld | 4,175 | $531.1K |
| May 1, 2026 | Touya Gael Segment Pres., CEO Designate | Award | 7,454 | $0 |
| May 1, 2026 | Gong Xiangwei President, Asia | Tax withheld | 2,559 | $304.6K |
| May 1, 2026 | Gong Xiangwei President, Asia | Award | 6,502 | $0 |
| May 1, 2026 | Ackerman Daniel Chief Accounting Officer | Award | 2,410 | $0 |
| May 1, 2026 | Prieur Marc Segment President | Award | 7,969 | $0 |
| May 1, 2026 | Hudson Irene Elizabeth EVP and Chief Legal Officer | Tax withheld | 247 | $29.4K |
| May 1, 2026 | Hudson Irene Elizabeth EVP and Chief Legal Officer | Award | 684 | $0 |
| May 1, 2026 | Tanda Stephan B. President and CEO | Tax withheld | 15,538 | $1.85M |
| May 1, 2026 | Tanda Stephan B. President and CEO | Award | 39,485 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for APTARGROUP, INC.
Free account. Everything above stays public.
Write why you follow APTARGROUP, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading